Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.
2.

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Barrett FS, Johnson MW, Griffiths RR.

J Psychopharmacol. 2015 Nov;29(11):1182-90. doi: 10.1177/0269881115609019. Epub 2015 Oct 6.

3.

Psychedelics and mental health: a population study.

Krebs TS, Johansen PØ.

PLoS One. 2013 Aug 19;8(8):e63972. doi: 10.1371/journal.pone.0063972. eCollection 2013.

4.

Values and beliefs of psychedelic drug users: a cross-cultural study.

Lerner M, Lyvers M.

J Psychoactive Drugs. 2006 Jun;38(2):143-7.

PMID:
16903453
5.

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Griffiths RR, Richards WA, McCann U, Jesse R.

Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. Epub 2006 Jul 7.

PMID:
16826400
6.

Psychedelic drugs and mystical experience.

Pahnke WN.

Int Psychiatry Clin. 1969;5(4):149-62. Review. No abstract available.

PMID:
4892137
7.

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Griffiths R, Richards W, Johnson M, McCann U, Jesse R.

J Psychopharmacol. 2008 Aug;22(6):621-32. doi: 10.1177/0269881108094300. Epub 2008 Jul 1.

8.

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

MacLean KA, Johnson MW, Griffiths RR.

J Psychopharmacol. 2011 Nov;25(11):1453-61. doi: 10.1177/0269881111420188. Epub 2011 Sep 28.

9.

The epistemic innocence of psychedelic states.

Letheby C.

Conscious Cogn. 2016 Jan;39:28-37. doi: 10.1016/j.concog.2015.11.012. Epub 2015 Dec 7. Review.

PMID:
26675408
10.

Psilocybin-induced stimulus control in the rat.

Winter JC, Rice KC, Amorosi DJ, Rabin RA.

Pharmacol Biochem Behav. 2007 Oct;87(4):472-80. Epub 2007 Jun 22.

11.

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R.

Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15.

12.

Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.

Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D.

Hum Psychopharmacol. 2012 Jul;27(4):352-63. doi: 10.1002/hup.2234. Epub 2012 Jun 14.

PMID:
22696164
13.

Altered states: psychedelics and anesthetics.

Icaza EE, Mashour GA.

Anesthesiology. 2013 Dec;119(6):1255-60. doi: 10.1097/01.anes.0000435635.42332.ee.

PMID:
24061599
14.

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu A, Griffiths RR, Johnson MW.

Curr Drug Abuse Rev. 2014;7(3):157-64.

15.

Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.

Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J.

Addict Behav. 2004 Jun;29(4):743-52.

PMID:
15135556
16.

'Candyflipping': synergistic discriminative effect of LSD and MDMA.

Schechter MD.

Eur J Pharmacol. 1998 Jan 12;341(2-3):131-4.

PMID:
9543229
17.

Psychedelic drugs: the ups and downs of ecstasy.

Check E.

Nature. 2004 May 13;429(6988):126-8. No abstract available.

PMID:
15141183
18.

A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.

Hallock RM, Dean A, Knecht ZA, Spencer J, Taverna EC.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):245-8. doi: 10.1016/j.drugalcdep.2012.11.010. Epub 2012 Dec 21.

PMID:
23265089
19.

Alterations of consciousness and mystical-type experiences after acute LSD in humans.

Liechti ME, Dolder PC, Schmid Y.

Psychopharmacology (Berl). 2017 May;234(9-10):1499-1510. doi: 10.1007/s00213-016-4453-0. Epub 2016 Oct 7.

Supplemental Content

Support Center